PP
NPCE icon

PDT Partners’s Neuropace NPCE Stock Holding History

PDT Partners’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,695
Closed -$264K – 680
2025
Q2 		$264K Buy
+23,695
New +$296K 0.01% 614

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PDT Partners's NPCE Position: Q3 2025 in Review

PDT Partners sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 23,695 shares — an estimated $264K sold.

PDT Partners first reported a position in NPCE in Q2 2025 and held it in 1 quarter. The position peaked at $264K in Q2 2025. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

  • PDT Partners reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
  • PDT Partners sold 23,695 Neuropace shares in Q3 2025, an estimated $264K.
  • PDT Partners first reported a position in Neuropace in Q2 2025 and held it in 1 quarter.
  • PDT Partners's Neuropace position peaked at $264K in Q2 2025.
  • 80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on PDT Partners's 13F filing for Q3 2025, filed 17 Nov 2025.